Slate Path Capital LP Arrowhead Pharmaceuticals, Inc. Transaction History
Slate Path Capital LP
- $4.98 Billion
- Q1 2024
A detailed history of Slate Path Capital LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Slate Path Capital LP holds 4,139,000 shares of ARWR stock, worth $108 Million. This represents 2.38% of its overall portfolio holdings.
Number of Shares
4,139,000
Previous 1,329,000
211.44%
Holding current value
$108 Million
Previous $40.7 Million
191.08%
% of portfolio
2.38%
Previous 0.91%
Shares
2 transactions
Others Institutions Holding ARWR
# of Institutions
296Shares Held
88.5MCall Options Held
905KPut Options Held
387K-
Black Rock Inc. New York, NY15.3MShares$399 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.4MShares$322 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.56MShares$222 Million2.95% of portfolio
-
State Street Corp Boston, MA6.56MShares$171 Million0.01% of portfolio
-
Artal Group S.A. Luxembourg, N43.04MShares$78.9 Million4.68% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.75B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...